The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.
While many studies have evaluated the use of drugs for quitting smoking among Whites, few have assessed efficacy with AAs. Racial/ethical differences in smoking are well documented. AAs smoke less than White smokers but experience disproportionately greater smoking disease and death. Past studies by the researchers in this study looked at how effective other smoking cessation methods are in AAs. These methods included nicotine gum, nicotine patch and buproprion sustained release. This study will be evaluating varenicline in both AA and White smokers. There has not been a study conducted yet to prospectively research AA-White differences in smoking cessation and also to examine potential causal pathways explaining AA-White differences in quitting.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
449
1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
University of Kansas Medical Center
Kansas City, Kansas, United States
Swope Health Central
Kansas City, Missouri, United States
Number of Participants With Cotinine-verified 7-day Point Prevalence Smoking Abstinence at Week 26
Defined as having no cigarettes for the previous 7 days at the Week 26 visit. The recommended cut-off of 15ng/ml for salivary cotinine will be used to differentiate smokers from non-smokers.
Time frame: Change from Baseline to Week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.